Business Wire

Alvarez & Marsal Appoints Four New Managing Directors in Its Paris Office

Del

Leading global professional services firm Alvarez & Marsal (A&M) has announced the appointment of four Paris-based Managing Directors, Jonathan Gibbons, Guillaume Martinez, Frederic Steiner and Donatien Chenu, to the firm’s Global Transaction Advisory Group. These appointments advance A&M’s strategic expansion plans to meet local market demand in France, enhance its cross-border M&A offering and help clients address increasingly complex regional, European and global regulatory requirements.

The addition of Messrs. Gibbons, Martinez, Steiner and Chenu, all formerly with one of the Big Four in France, completes the latest phase of A&M’s European strategic growth plan following the launch of the firm’s Stockholm office and Nordics expansion in 2017 that added to existing transaction advisory activities in the U.K., Germany, and Netherlands. They will bolster A&M’s suite of integrated global transaction advisory services that provide clients with a differentiated offering for due diligence and transaction advisory requirements.

A&M’s market share continues to expand with the firm’s European practices experiencing strong growth over the past two years leading to work on a range of flagship European private equity deals. With A&M’s operational focus and market leading capabilities in Private Equity and Corporate Performance Improvement, A&M is uniquely placed to provide a differentiated approach to due diligence and take on the challenges of current market conditions faced by clients.

Antonio "Tony" Alvarez III, Managing Director and A&M’s European Practice lead, said, “These appointments support our global expansion strategy along with our capability building plans in France and Europe. New audit regulation and rotation rules are impacting the provision of non-audit services and generating greater conflicts in providing those services to clients. As growing numbers of Big Four professionals across Europe look beyond the traditional firms, A&M’s platform is acknowledged to be less restrictive enabling greater access for practice growth.”

Paul Aversano, Managing Director and Global Practice Leader of A&M’s Global Transaction Advisory Group, said, “The growth of our transaction advisory presence in France supports the firm’s commitment to meet local market needs and global market M&A demands with our unique and differentiated approach. These appointments are the latest of several growth areas in France and Europe for A&M to enable us to continue our European expansion.”

Managing Director and European Practice Lead with A&M’s Transaction Advisory Group, David Evans, added, “Jonathan’s, Guillaume’s, Frederic’s, and Donatien’s in-depth knowledge advances our ability to help private equity firms and corporate clients maximize value on a pan-European basis. We expect the French team to grow rapidly as client needs continue to escalate.”

Tarek Hosni, the France country leader and Managing Director with A&M Paris, stated, “The addition of these senior transaction professionals will enable us to increase our scale and service for French private equity firms as well as France based multinationals. A leading protagonist of positive transformation in France, we now also intend to deliver in France our internationally recognized expertise in transaction advisory services. This marks the start of our future growth plans for A&M France.”

A&M’s new Transaction Advisory Managing Directors have extensive cross-border and global transaction experience working with private equity and multi-national corporations throughout Europe and the world. The team’s collective experience spans numerous sectors including TMT, manufacturing, retail and consumer goods and financial services. For more information on Messrs. Gibbons, Martinez, Steiner and Chenu, please click on the links to their bios below:

Jonathan Gibbons

Guillaume Martinez

Frederic Steiner

Donatien Chenu

About Alvarez & Marsal

Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) when conventional approaches are not enough to make change and achieve results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services.

With over 3000 people across four continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, help organizations transform operations, catapult growth and accelerate results through decisive action. Comprised of experienced operators, world-class consultants, former regulators and industry authorities, A&M leverages its restructuring heritage to turn change into a strategic business asset, manage risk and unlock value at every stage of growth.

When action matters, find us at alvarezandmarsal.com. Follow A&M on LinkedInTwitter and Facebook.

Note to Editor:

About Alvarez & Marsal Global Transaction Advisory Group

A&M’s Global Transaction Advisory Group provides investors and lenders the answers needed to get the deal done. We combine our firm’s deep operational, industry and functional resources with Big Four-quality financial accounting and tax expertise to assess key deal drivers and focus on the root cause of any critical deal issues. As the largest transaction advisory practice outside the Big Four, our global integrated teams help private equity, sovereign wealth funds, family offices and hedge funds as well as corporate acquirers unlock value across the investment lifecycle.

The firm’s Global Transaction Advisory Group includes over 350 professionals in 22 offices throughout the U.S., Latin America, Europe, India and Asia. Our global team has extensive industry knowledge across multiple sectors including, but not limited to, dedicated industry verticals in healthcare, software & technology, energy and financial services.

Contact information

Alvarez & Marsal
Helene Willberg, +46 70 589 9763
Managing Director
or
Sandra Sokoloff, +1 212-763-9853
Senior Director of Global Public Relations
or
Margaret Cameron-Waller, +44 (0)207 7155202
Director of Marketing U.K. & Europe

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha

Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 07:58Pressemelding

Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs